Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents.
Following androgen ablation therapy, skeletal metastases from prostate cancer appear in some instances to show an increase in 99Tcm-methylene diphosphonate (99Tcm-MDP) uptake. Such a phenomenon could represent a mechanism to increase delivery of bone-seeking therapeutic agents to skeletal metastatic sites. The aim of this study was to characterize more precisely the potential increase in 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone therapy. Baseline bone scans were performed within 1 week of onset of hormone therapy in patients with stage D2 prostate cancer followed by multiple repeat bone scans for up to 4-6 weeks. The count density within metastatic lesions was divided by the average count density from several areas of normal bone to obtain a lesion to normal bone uptake ratio (L/N) for each lesion in each scan. Altogether, 61 skeletal metastases were identified on bone scans from five subjects. Eighty-four percent (51/61) of these lesions showed an increase in 99Tcm-MDP activity relative to normal bone following initiation of hormone therapy with a mean peak increase of 39%. Thirty-nine of these 51 metastatic lesions showed maximum uptake at 3 weeks post-onset of hormone treatment. From our findings, it appears that approximately 3 weeks following initiation of hormone blockade, most skeletal metastases from prostate cancer will demonstrate significantly enhanced 99Tcm uptake relative to normal bone. Consequently, it may be possible to improve the uptake and effectiveness of therapeutic bone-seeking radiopharmaceuticals by administering these agents following hormone therapy in patients with prostate cancer metastases.
Bushnell
D L
DL
VA Medical Center, Iowa City, IA, USA. david-bushnell@uiowa.edu
Madsen
M
M
Kahn
D
D
Nathan
M
M
Williams
R D
RD
D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000378:metabolism; D000813:Anilides / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D001842:Bone and Bones / Q000201:enzymology; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000494:pharmacology; D006728:Hormones / Q000494:pharmacology*; D006801:Humans; D008297:Male; D009570:Nitriles; D015675:Osteocalcin / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D013669:Technetium Tc 99m Medronate / Q000493:pharmacokinetics*; D014105:Tosyl Compounds
D000813:Anilides; D000970:Antineoplastic Agents; D006728:Hormones; D009570:Nitriles; D019275:Radiopharmaceuticals; D014105:Tosyl Compounds; D015675:Osteocalcin; D007987:Gonadotropin-Releasing Hormone; C053541:bicalutamide; D000469:Alkaline Phosphatase; D013669:Technetium Tc 99m Medronate